Quest Diagnostics consensus and sector context, shares on the NYSE radar
30.06.2026 - 11:13:44 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-30, 11:13.
Quest Diagnostics (US74834L1008) starts this week as one of the established US laboratory testing names on the NYSE. The focus for investors is on analyst consensus, sector positioning and recent trading levels in the broader S&P 500 healthcare universe.
Analyst views and valuation markers
Sell-side coverage on Quest Diagnostics typically comes from large US and European brokerages that follow the diagnostics space alongside peers such as Labcorp and Eurofins. Ratings in recent months have generally clustered around Hold and Buy, with price targets often set using earnings and cash flow multiples.
Research houses frequently compare Quest Diagnostics to competitors like Labcorp and to diversified diagnostics arms at larger groups such as Abbott Laboratories or Roche. They usually look at metrics like organic revenue growth, margin trends and free cash flow conversion when calibrating ratings and valuation ranges.
Consensus expectations for earnings
For many investors, the starting point is consensus data aggregating forecasts from several banks and independent firms. These summaries usually provide estimates for revenue, earnings per share and margins over a multi-year horizon, often three years ahead.
Quest Diagnostics is commonly modeled as a relatively stable cash generative business, with analysts tracking test volumes, reimbursement dynamics from US payers and cost efficiency programs. Deviations from consensus in quarterly reports can move the shares when the company reports earnings on the NYSE.
Background and price data on Quest Diagnostics
More articles and key figures help investors see how Quest Diagnostics shares trade over time and how news flow affects the valuation.
What the company sells
Quest Diagnostics generates most of its revenue from diagnostic information services, including routine blood tests, specialized molecular diagnostics and screening services ordered by physicians, hospitals, employers and health plans. The company also offers health IT and analytics solutions to support clinical decision-making and population health management.
Where the stock trades today
Quest Diagnostics shares (US74834L1008) trade on the NYSE under the ticker DGX. On 2026-06-30 at 11:13 US Eastern time, the last verifiable indicative price was not available in this dataset, but trading remains in US dollars on the primary US venue.
Key data on the Quest Diagnostics shares
- Company: Quest Diagnostics Incorporated
- ISIN: US74834L1008
- WKN: 916895
- Ticker: DGX
- Trading venue: NYSE
- Price (as of 2026-06-30, 11:13): not available USD
- Market cap: data not verified for this timestamp
- Sector / industry: Health Care / Diagnostics & Research
- Index membership: S&P 500
- Next earnings date: not officially scheduled
Disclaimer: This article is for informational purposes only and does not constitute investment advice, investment recommendation or an offer to buy or sell securities. All information has been compiled with care, but no guarantee is given for completeness or accuracy. Investors should make their own decisions and, if necessary, consult a professional advisor.
